Rilvegostomig: Data from P2b GEMINI-Hepatobiliary trial (NCT05775159) for HCC and biliary tract cancer in 2026 (AstraZeneca) - Feb 6, 2025 - Q4 & FY2024 Results: Data from P3 ARTEMIDE-Biliary01 trial (NCT06109779) for biliary tract cancer post 2026
P2 data • P3 data • Biliary Tract Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology
|